ArticleiScience2023

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.

Antonio Barreiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.